Director of Commercial Development Twist Bioscience, United States
Next-generation sequencing (NGS) has revolutionized cancer research and clinical oncology through comprehensive molecular tumor characterization. This presentation explores three transformative NGS applications reshaping cancer diagnostics and monitoring. Custom panels enable targeted, cost-effective sequencing of clinically relevant mutations, providing actionable insights for personalized treatment. Liquid biopsy approaches utilize cell-free DNA and circulating tumor cells for non-invasive cancer detection, real-time treatment monitoring, and early resistance identification. Methylation profiling leverages epigenetic signatures to improve tumor classification, identify tissue of origin, and detect early-stage cancers when most treatable. Together, these NGS-based technologies accelerate precision oncology, improve patient outcomes, and open new avenues for understanding cancer biology.
